How accurate are gallium-68 PSMA PET/CT scans in the “real world”?

A new article in the journal Cancer Imaging has provided us with an interesting set of “real world” data on the accuracy of gallium-68 PSMA PET/CT scans in the management of prostate cancer. … READ MORE …

Lutetium-177 PSMA-617 in Phase III (VISION) trial for treatment of mCRPC

We have just been appraised of a randomized, double-blind, multi-center, Phase III clinical trial of the targeted, radiolabeled agent 177Lu-PSMA-617 (a form of “radioligand” therapy) in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Novartis acquires developers of Lu-177 PSMA-617 and Ac-225 PSMA-617

The major, Switzerland-based, global pharmaceutical company Novartis has just agreed to acquire Endocyte — the developer of both Lu-177- PSMA-617 and Ac-225-PSMA-617, which are in clinical trials for the treatment of advanced forms of prostate cancer. … READ MORE …

Gallium-68 PSMA PET scanning “is a game changer” in prostate cancer

The “game changer” statement above comes from an independent review of the potential value of gallium-86-labeled prostate-specific molecular antigen (68Ga PSMA) PET scanning in the evaluation of selected men with prostate cancer. … READ MORE …

Progenics reports outcome of OSPREY 2301 trial of PyL™

In a media release issued earlier this morning, Progenics Pharmaceuticals has announced the outcome of a Phase II/III trial of their proprietary, PSMA-targeted imaging agent PyL (also known as 18F-DCFPyL) for identification of prostate cancer. … READ MORE …

Gallium-68 PET/CT scans prior to first-line treatment of some men with prostate cancer

A newly-reported set of data from an Australian clinical research team has now shown that 68Ga PSMA PET/CT scans changed the staging and the management of men after initial diagnosis and prior to first-line treatment compared to traditional CT and bone scanning. … READ MORE …

Trial of new imaging agent nears completion

Early this morning, Progenics Pharmaceuticals announced completion of enrollment of patients in the Phase II/III OSPREY trial of a new PSMA-targeted PET/CT imaging agent for detection of prostate cancer. … READ MORE …